Table 2.

Histologic subtypes of MMR-deficient ovarian cancers

Reference	Sample size	Serous	Mucinous	Endometrioid	Clear cell
HNPCC-associated ovarian cancers
Aarnio et al., 1999 (40)	13	4	2	1	2
Bewtra et al., 1992 (3)	4	1	0	1	2
Crijnen et al., 2005 (13)	26	12	1	4	1
Ichikawa et al., 1999 (43)	4	2	1	1	0
Stratton et al., 1999 (46)	2	0	1	1	0
Watson et al., 2001 (47)	79	17	7	13	7
MSI-H ovarian cancers
Chiaravalli et al., 2001 (41)	4	0	3	1	0
Dellas et al., 2004 (25)	20	11	3	3	1
Fujita et al., 1995 (26)	8	2	1	5	0
Geisler et al., 2003 (10)	21	12	2	6	0
Gras et al., 2001 (11)	2	0	0	1	1
King et al., 1995 (29)	7	2	0	2	1
Sood et al., 2001 (35)	13	7	N/A	N/A	N/A
Ovarian cancers with loss of MMR protein expression
Domanska et al., 2007 (42)	6	0	1	3	2
Malander et al., 2006 (44)	3	0	1	0	1
Rosen et al., 2006 (45)	7	0	0	1	2

Undifferentiated	Unspecified	Mixed	Nonepithelial*	Nonserous proportions†
0	4	0	0	5/9 (56%)
0	0	0	0	3/4 (75%)
1	1	0	4	7/19 (37%)‡
0	0	0	0	2/4 (50%)
0	0	0	N/A	2/2 (100%)
0	26	4	5	31/48 (65%)
0	0	0	0	4/4 (100%)
0	2	0	N/A	7/18 (39%)
0	0	0	N/A	6/8 (75%)
0	1	0	0	8/20 (40%)
0	0	0	0	2/2 (100%)
0	0	1	1	4/6 (67%)
N/A	N/A	N/A	N/A	6/13 (46%)
0	0	0	N/A	6/6 (100%)
0	0	1	N/A	3/3 (100%)
0	0	3	1	6/6 (100%)

Abbreviation: N/A, not applicable.

^*Studies where only epithelial ovarian cancers were included, N/A (not applicable) is indicated in this column, as nonepithelial ovarian cancers were not included in these studies.

^†Unspecified adenocarcinomas and nonepithelial cancers were not included within the denominator.

^‡Two histologic subtypes were unknown, thus not included in the percentage.

NOTE: This reference included within the table was omitted from the analysis presented within the paper owing to lack of information regarding the specific histologic subtypes of the non-serious cancers.